维持性血液透析皮肤瘙痒患者使用舒缓止痒护肤乳阳性筛查研究

注册号:

Registration number:

ChiCTR2500112990 

最近更新日期:

Date of Last Refreshed on:

2025-11-21 17:48:11 

注册时间:

Date of Registration:

2025-11-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

维持性血液透析皮肤瘙痒患者使用舒缓止痒护肤乳阳性筛查研究

Public title:

Positive screening for the use of soothing anti-itch skin lotion in patients with pruritus undergoing maintenance haemodialysis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

维持性血液透析皮肤瘙痒患者使用舒缓止痒护肤乳阳性筛查研究

Scientific title:

Positive screening for the use of soothing anti-itch skin lotion in patients with pruritus undergoing maintenance haemodialysis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘宛怡 

研究负责人:

毛楠 

Applicant:

Wanyi Liu 

Study leader:

Nan Mao 

申请注册联系人电话:

Applicant telephone:

+86 181 4038 6577

研究负责人电话:

Study leader's
telephone:

+86 155 2846 1208

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuwanyid@163.com

研究负责人电子邮件:

Study leader's E-mail:

maonanlyb@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市新都区新都大道783号,邮编:610599

研究负责人通讯地址:

四川省成都市新都区宝光大道中段278号

Applicant address:

No. 783 Xindu Avenue, Xindu District, Chengdu, Sichuan, 610599, P.R. China

Study leader's address:

No. 278, Middle Section of Baoguang Avenue, Xindu District, Chengdu City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都医学院护理学院

Applicant's institution:

School of Nursing, Chengdu Medical College

研究负责人所在单位:

成都医学院第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Chengdu Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025CYFYIRB-BA-120

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都医学院第一附属医院医学伦理委员会

Name of the ethic committee:

The First Affiliated Hospital of Chengdu Medical CollegeIRB Review

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-22 00:00:00

伦理委员会联系人:

陈虎

Contact Name of the ethic committee:

Chen Hu

伦理委员会联系地址:

四川省成都市新都区宝光大道中段278号成都医学院第一附属医院科教楼2楼医学伦理委员会办公室

Contact Address of the ethic committee:

Office of the Medical Ethics Committee Second Floor, Academic Building The First Affiliated Hospital of Chengdu Medical College 278 Baoguang Avenue Middle Section Xindu District Chengdu City Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 8111 2507

伦理委员会联系人邮箱:

Contact email of the ethic committee:

cyfylunli@163.com

研究实施负责(组长)单位:

成都医学院第一附属医院

Primary sponsor:

The First Affiliated Hospital of Chengdu Medical College

研究实施负责(组长)单位地址:

四川省成都市新都区宝光大道中段278号

Primary sponsor's address:

No. 278, Middle Section of Baoguang Avenue, Xindu District, Chengdu City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan Province

City:

单位(医院):

成都医学院第一附属医院

具体地址:

四川省成都市新都区宝光大道中段278号

Institution
hospital:

The First Affiliated Hospital of Chengdu Medical College

Address:

No. 278, Middle Section of Baoguang Avenue, Xindu District, Chengdu City, Sichuan Province

经费或物资来源:

四川省老年医学临床医学研究中心重点项目(24LNYXSSA04)

Source(s) of funding:

Key Project of the Sichuan Provincial Clinical Research Centre for Geriatric Medicine (24LNYXSSA04)

研究疾病:

维持性血液透析  

Target disease:

Maintenance hemodialysis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

观察舒缓止痒护肤乳缓解瘙痒的主观感受;评估舒缓止痒护肤乳安全性(皮肤不良反应);了解患者接受度和依从性;探索其对皮肤屏障功能的改善情况。  

Objectives of Study:

Observe subjective experiences of itch relief with the soothing anti-itch skin care lotion; Evaluate the safety profile of the soothing anti-itch skin care lotion (skin adverse reactions); Assess patient acceptance and adherence; Investigate its effects on improving skin barrier function.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

符合以下任一条者应予以排除 (1)对皮肤外用药物过敏者;(2)研究部位皮肤存在活动性感染、破损或严重炎症性皮肤病变;(3)预计生存期较短或已纳入肾移植计划者;(4)合并严重精神疾病或认知功能障碍,无法配合完成研究过程;(5)目前正在参与其他干预性临床研究;(6)研究者根据医学判断认为不适合参与本研究的其他情况。

Exclusion criteria:

Exclude any subject meeting any of the following criteria: (1) Individuals with a history of allergic reactions to topical dermatological medications; (2) Active infection, skin lesions, or severe inflammatory skin conditions at the study site; (3) Patients with a shortened life expectancy or those already enrolled in a kidney transplant program; (4) Individuals with severe psychiatric disorders or cognitive impairment preventing participation in the study process; (5) Participants currently enrolled in other interventional clinical trials; (6) Other circumstances where the investigator, based on medical judgment, deems participation in this study inappropriate.

研究实施时间:

Study execute time:

From 2025-09-22 00:00:00 To 2026-09-22 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-11-21 00:00:00 To 2026-09-22 00:00:00

干预措施:

Interventions:

组别:

本研究采用前瞻性自身前后对照设计,根据患者瘙痒严重程度(VAS 0-10 分) 分层实施观察与评估。

样本量:

80

Group:

This study employed a prospective, self-controlled design, with observation and assessment stratified according to the severity of patient itching (VAS score 0–10).

Sample size:

干预措施:

所有入组者均由研究人员在非透析期间使用“舒缓止痒护肤乳”,均匀涂抹于患者自述瘙痒部位。

干预措施代码:

Intervention:

All participants were instructed by researchers to apply the "Soothing Anti-Itch Skin Lotion" evenly to areas reported as itchy by the patients during non-dialysis periods.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan Province

City:

单位(医院):

成都医学院第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Chengdu Medical College

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

瘙痒视觉模拟评分

指标类型:

主要指标

Outcome:

VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究数据采集和管理包括病例记录表,用于记录血透患者的基本信息、瘙痒程度、用药情况等;同时采用自行设计的记录方式,对数据进行规范收集与管理,确保数据的准确性和完整性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management for this study encompassed case record forms used to document haemodialysis patients' basic information, itch severity, medication details, and other relevant data. Concurrently, a bespoke recording methodology was employed to ensure standardised data collection and management, thereby safeguarding data accuracy and completeness.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-21 17:48:05